

PDE4D Antibody FITC Conjugated

Catalog No: #C02457F

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description

Product Name	PDE4D Antibody FITC Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	Flow-Cyt IF
Species Reactivity	Hu Ms Rt
Immunogen Description	KLH conjugated synthetic peptide derived from human PDE4D
Conjugates	FITC
Target Name	PDE4D
Other Names	cAMP specic 3',5' cyclic phosphodiesterase 4D; DKFZp686M11213; FLJ97311; cAMP specic 3' 5' cyclic phosphodiesterase 4D; cAMP specic phosphodiesterase 4D; cAMP specic phosphodiesterase PDE4D; cAMP specic phosphodiesterase PDE4D6; cyclic AMP phosphodiesterase; DPDE 3; DPDE3; Duncce like phosphodiestera
Accession No.	NCBI Gene ID5144
Uniprot	Q08499
GeneID	5144;
Excitation Emission	494nm 518nm
Concentration	1mg ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Application Details

Flow-Cyt=2ug/Test IF=1:50-200

Background

Cyclic AMP-dependent phosphodiesterase type D (PDE4D) family is comprise of 5 variants (PDE4D1, D2, D3, D4 and D5). One or more PDE4D subtype variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype variants are expressed in varying ratios and their activity is regulated in tandem with GPCRs stimulation. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1 D2 mRNA levels rise in response to an increase in cAMP. Short term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein protein interactions with cytoskeletal scaffolding proteins.

Note: This product is for in vitro research use only